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Synthesis of somatostatin by breast cancer cells and their inhibition by
exogenous somatostatin and sandostatin
J. Nelson, M. Cremin & R.F. Murphy
Department of Biochemistry, The Queen's University of Belfast, 97 Lisburn Road, Belfast BT9 7BL, UK.
Summary Three human breast cancer cell lines ZR-75-1, MDA-MB-436 and MCF-7 were found to contain
respectively, 3.06, 2.69 and 1.86fmol of somatostatin-like immunoreactivity (SLI) per 106 cells. Since SLI is
undetectable in the passaging media it must, therefore, be synthesised by the cells. In the presence of fetal calf
serum the cells were growth inhibited by addition of somatostatin or its long-lasting analogue, Sandostatin,
but only after 3 days of continuous exposure. A 1-day exposure to either peptide had little or no effect on
subsequent cell growth in peptide-free medium. Inhibition of cell proliferation is not due to cytotoxic effects
of the dose used (500ngml-1, each) since both peptides caused short-term stimulation of growth in the
absence of serum.
Somatostatin is a neuroendocrine hormone which inhibits
not only exocrine and endocrine secretion, but also mito-
genesis. Somatostatin-synthesising cells have a widespread
anatomical distribution, being found in regions of the central
nervous system and gastrointestinal tract. In the rat
somatostatin-like immunoreactivity (SLI) is particularly con-
centrated in the hypothalamus, pancreas and pyloric antrum
but is undetectable in lung, liver, kidney, adrenal, submandi-
bular glands or celiac plexus (Patel & Reichlin, 1978). The
results for mammary glands were not reported.
There have been few studies of the presence of SLI in
breast cancer specimens. A survey of the relevant literature
shows the incidence of somatostatin synthesis to be uncom-
mon: six out of 74 cases (Nesland et al., 1985; Nesland &
Holm, 1986; Spring-Mills et al., 1984; Hull & Warfel, 1987;
Cross et al., 1985). No information is available regarding
SLI in normal breast, but SLI was absent in four benign
mammary displasias (Spring-Mills et al., 1984). The presence
of somatostatin receptors is also an uncommon feature of
breast cancer: three out of 39 cases (Reubi et al., 1987).
Anti-tumour effects of long-lasting peptide analogues of
somatostatin (such as SMS 201-995, 'Sandostatin') have been
achieved clinically in hypersecretory neuroendocrine
tumours; relief of symptoms is due to inhibition of peptide
secretion but arrest of tumour growth has also been noted
(Anderson & Bloom, 1986). Somatostatin and its analogues
inhibit mammary tumour growth in vivo (Vuc-Pavlovic et al.,
1982; Klijn et al., 1986). Inhibition of tumour growth may
be indirect, through inhibition of endocrine secretion. For
example, synthetic linear somatostatin inhibits the prolife-
ration of murine mammary aplastic carcinoma in vivo by
suppression of exogenous insulin and tumour-secreted
insulin-like immunoreactivity (Vuc-Pavlovic et al., 1982).
Inhibition of growth may also be direct, through interaction
with receptors on the target cells. The human breast cancer
cell line, MCF-7, has high affinity receptors for, and is
inhibited by somatostatin analogues in vitro (Klijn et al.,
1986; Setyono-Han et al., 1987).
In this report we confirm the growth inhibitory effects of
Sandostatin and somatostatin on the oestrogen receptor-
positive human breast cancer cell lines, MCF-7 (Setyono-
Han et al., 1987) and ZR-75-1 (Scambia et al., 1988) and
have demonstrated growth inhibition by both native peptide
and analogue on the oestrogen receptor-negative line, MDA-
MB-436. The growth inhibitory effects were found to be
dependent on factor(s) in the serum component of the tissue
culture media.
Results presented show, for the first time, the presence of
somatostatin-like immunoreactivity in breast cancer cells in
culture.
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Materials and methods
Tissue culture
All media and fetal calf serum (FCS) were obtained from
Flow Laboratories, Rickmansworth, UK. The same batch of
serum was used throughout.
MCF-7 cells, a gift from Dr C.R. Green, Liverpool
University, were routinely cultured in modified Eagle's mini-
mal essential medium (MEM) supplemented with non-
essential amino acids, sodium pyruvate (1 mM) and 5% v/v
FCS. ZR-75-1 and MDA-MB-436 cells were obtained from
the American Tissue Culture Collection. ZR-75-1 cells were
cultured in RPMI 1640 medium containing 5% FCS. MDA-
MB-436 cells were cultured in Liebowitz 15 medium contain-
ing 10% FCS. All media contained Phenol Red and were
supplemented with penicillin (1OOIUml-1) and streptomycin
(100 ugml-1).
Cell proliferation assays
To assess the effects of somatostatin and Sandostatin,
5 x 104 cells were inoculated in 24-well tissue culture plates
(Costar, Northumbria Biologicals Ltd, Cramlington, UK)-
.After one day, plating efficiency was determined in a repre-
sentative set of wells (cell counts, day 0) by trypsinisation
and electronic cell counting (Coulter counter model ZBI,
Coulter Electronics, Luton, UK). At this time medium was
removed from remaining wells and replaced with fresh
medium (control) or medium containing peptide (treatment)
as indicated. Control and treatment media were either
unchanged or changed daily during the course of the experi-
ments, or control and treatment media were removed after
one day exposure (i.e. from day 0 to day 1) and replaced by
control medium. Thereafter cells were removed and counted
at the times indicated.
Radioimmunoassay of somatostatin-like material
Cells (1-5 x 108) were harvested by gentle scraping from
125cm2 flasks into phosphate-buffered saline (pH 7.4). Cells
were pelleted and extracted with acidified ethanol (95% in
I NHCI) by repeated syringing followed by shaking for 2h at
4°C. The extract was centrifuged at 100,OOOg, 1 h and the
resulting supernatant was evaporated to dryness in a rotary
evaporator. The residue was reconstituted in 1-2ml of
binding buffer (50mM sodium phosphate buffer, pH 7.2,
containing 0.3% BSA and 10mM EDTA) and pH was
adjusted to neutrality, as required.
Antiserum to somatostatin-14 (Biogenesis, UK) at a final
dilution of 1:2400, 1251-Tyr11somatostatin-14 (Amersham,
UK) 3,000c.p.m. and unlabelled somatostatin-14 (Sigma,
USA) 2-500fmol, or cell extract were added, in triplicate, to
a series of microcentrifuge tubes and made up to a final
volume of 0.4ml with binding buffer. Tubes were incubated
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for 20h at 4°C. Unbound label was then removed by
addition of 10mg acid-washed charcoal and 1 mg Dextran
T-70 in 0.5 ml binding buffer followed by centrifugation.
Bound and free label were quantified by gamma counting.
Results
Cell proliferation
In initial experiments a range of concentrations of somato-
statin, 10-500ngml-1 (6x10-9 to 3x10-7M) and Sandos-
tatin, 10-500ngml-1 (lx 10-8 to 5x 10-7M) were tested,
without medium changes, for growth inhibition of MCF-7,
MDA-MB-436 and ZR-75-1 cells. Inhibition was occasion-
ally observed with either peptide at concentrations as low
as 25ngml-1 The inhibition at low concentrations, however,
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Figure 1 Effect of somatostatin on ZR-75-1 cell proliferation in
the presence of 5% FCS. (a) Medium changed daily. (b) medium
unchanged during course of experiment. (c) One day exposure,
i.e. treatment and control media replaced by control medium on
day 1. 0, control; *, treatment, 500 ngml- somatostatin.
Results are mean cell numbers+s.d. (bars) of four wells. Signifi-
cant differences between treatment and control are indicated
(*P<0.01, Student's t test). Error bars not shown where the
symbol overlaps.
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Figure 2 Effect of Sandostatin on ZR-75-1 cell proliferation in
the presence of 5% FCS. (a) Medium changed daily. (b) One day
exposure, i.e. treatment and control media replaced by control
medium on day 1. 0, control; *, treatment, 500ngml-1 Sando-
statin. Results are mean cell numbers+s.d. (bars) of three wells.
Significant differences between treatment and control are indi-
cated (*P<0.01, Student's t test). Error bars not shown where
the symbol overlaps.
was variable and consistent inhibition of growth was only
found with 500ng ml-' of either peptide.
Representative growth experiments are presented; all
results have been confirmed in at least two independent
determinations (Figures 1-4).
In standard passaging medium (RPMI 1640 containing
5% FCS) continuous exposure to somatostatin causes signifl-
cant inhibition of ZR-75-1 cell proliferation from day 3
onwards, regardless of frequency of medium changes (Figure
la and b). In contrast to the results of Setyono-Han et al.
(1987) the inhibitory effects of somatostatin and Sandostatin
were not more pronounced in the presence of insulin (results
not shown). Daily changes of medium allow the control cells
to grow faster and reach a higher density but the magnitude
of reduction of cell numbers below relevant control values
with daily replacement of somatostatin-containing medium
(Figure la) is the same (>3-fold on days 6 and 9) as in
experiments where the somatostatin-containing medium is
unchanged during the course of study (Figure lb). In the
above conditions exogenous somatostatin, as measured by
RIA, is reduced to <20% (in the presence of cells and 5%
FCS) or <50% (in the presence of 5% FCS alone) after one
day incubation, and is undetectable after two days in 5%
FCS with or without cells.
Figure lc shows the results of a one day exposure to
somatostatin followed by 8 days recovery without medium
changes. There is no significant difference between control or
treatment cell numbers at any stage. Continuous exposure to
500ngml -1 Sandostatin causes inhibition of ZR-75-1 cell
proliferation on day 6 to an extent similar to that of
continuous exposure to somatostatin (Figure 2a) but a one
day exposure to Sandostatin followed by return to control
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Figure 3 Effect of continuous exposure to somatostatin on ZR-
75-1 cell proliferation in serum-free medium. 0, control; 0,
treatment, 500 ngml - 1 somatostatin. Results are mean cell
numbers+s.d. (bars) of four wells. Significant differences between
treatment and control are indicated (*P<0.01, Student's t test).
Error bars not shown where the symbol overlaps.
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Figure 4 Effect of 6 days continuous exposure, without medium
changes, to either somatostatin or Sandostatin on final cell
numbers of ZR-75-1, MDA-MB-436 and MCF-7 cells in the
presence of 5% FCS. Cl, control; Ti, treatment, 500ngml-'
somatostatin; C2, control; T2, treatment, 500 ngml-
1 Sandosta-
tin. Results are mean cell numbers+s.d. (bars) of 3-5 wells.
Significant differences between treatment and control are indi-
cated (*P<0.01, Student's t test).
medium is much less effective in inhibiting cell proliferation
than a continuous exposure (Figure 2a and b).
The growth inhibition caused by 500ngml-1 somatostatin
is not due to cytotoxic effects since, while there is no
significant growth of control cells in the first day after
exposure (day 0 to day 1), there is stimulation of growth of
treated cells, and for the next two days treated cell numbers
remain higher than controls (Figure 3). Floating cells are
undetectable during the course of study. Similar results are
obtained with Sandostatin in serum-free conditions and the
slight protective effect of both peptides is not altered if
medium is changed daily (results not shown).
Results in Figure 4 show that continuous exposure to
somatostatin or Sandostatin also causes inhibition of growth
of MDA-MB-436 and MCF-7 cells in their standard passag-
ing media (respectively, L-15 plus 10% FCS and MEM plus
5% FCS). The effect of a one day exposure to somatostatin
on MDA-MB-436 and MCF-7 cells is similar to the effect on
ZR-75-1 cells, in that treatment and control cell numbers are
not significantly different (results not shown). As in the case
of ZR-75-1 cells, somatostatin showed no cytotoxic effects
towards MDA-MB-436 cells in serum-free conditions (results
not shown).
fmol per tube
Figure 5 El, Somatostatin RIA calibration curve. *, MDA-
MB-436 cell extract.
Somatostatin-like immunoreactivity
ZR-75-1, MDA-MB-436 and MCF-7 cells were extracted
and assayed for the presence of SLI. Under standard
conditions of culture the following intracellular levels ol' SLI
were found: ZR-75-1, 3.06fmol per 106 cells; MDA-MB-436.
2.69fmol per 106 cells; MCF-7, 1.86fmol per 106 cells. The
RIA was insensitive to Sandostatin (500fmol per tube);
bacitracin, EGF (1,000fmol per tube); leupeptin, prolactin
(2,000fmol per tube) but displacement of label was found
with somatostatin-28 at higher molarities than
somatostatin-14.
The FCS batch used in these experiments was assayed
both directly and as an acid-ethanol extract and in both
cases SLI could not be detected. In direct assay of undiluted
FCS displacement of label was observed but dilution did not
parallel calibration curve; FCS extracts produced no displa-
cement. Dilution series of extracts from the cell lines did,
however, parallel the calibration curve.
The results for MDA-MB-436 cell extract are shown in
Figure 5. SLI could not be detected in conditioned media
but extraction and concentration of the media may reveal
low levels of secreted SLI. This possibility is being
investigated.
Discussion
Continuous exposure to either single or repeated doses of
500 ngml- 1 of either somatostatin or Sandostatin in the
presence of FCS produces similar inhibition (>3-fold, day 6)
of ZR-75-1 cell proliferation compared with relevant control
populations (Figures Ia, b and 2a). After only one day
exposure there is little or no subsequent inhibition of growth
in peptide-free medium (Figures Ic and 2b). In serum-free
conditions neither peptide causes immediate cell death,
making unlikely the possibility that the inhibition observed
in the presence of serum is due to non-specific toxic effects
of the peptides.
The growth inhibitory effect of somatostatin becomes
apparent only after somatostatin drops to undetectable levels
during continuous exposure experiments and significant inhi-
bition persists up to day 9. This may be explained by
presence of active degradation products which are undetec-
table by RIA, or by a delayed secretion of modulatory
substances induced by somatostatin. The concentration of
secondary growth inhibitory substances in the medium
would be reduced by treatment withdrawal (in exposure/
recovery experiments, Figure lc) but would build up during
continuous exposure (no medium changes, Figure lb) and
would be replenished after each application of peptide
during daily medium changes (Figure la).
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Sandostatin is a long-lasting analogue of somatostatin.
Rat kidney homogenates, for example, degrade somatostatin
to <25% of starting levels within 1 h whereas Sandostatin is
virtually unaffected for up to 20h (Pless et al., 1986). It is
likely that a saturating dose of Sandostatin remains receptor-
bound after the drug is removed. A one day exposure to
Sandostatin, however, causes much less subsequent inhibition
of growth in drug-free medium than does continuous expo-
sure during the whole experiment. This suggests that initial
receptor occupancy is not sufficient to account for the
inhibition seen in continuous exposure to either peptide.
Setyono-Han et al. (1987) found doses of Sandostatin
above 1 X 10-8 M to be decreasingly growth inhibitory. In
contrast, we found concentrations above 1 X 10-8M to be
increasingly growth inhibitory, which is in agreement with
the findings of Scambia et al. (1988).
Somatostatin is undetectable in the fetal calf serum used in
this investigation. The cell-associated SLI must, therefore, be
synthesised by the cells. The small amounts of somatostatin-
like material synthesised by the cells may result in saturation
of high affinity, low capacity binding sites and their down-
regulation. It is possible that somatostatin and Sandostatin
exert growth inhibitory effects through low affinity as well as
high affinity sites. Low affinity somatostatin-binding sites
have been reported (Leitner et al., 1979; Arilla et al., 1984).
Preliminary results have shown that the breast cancer cells
cultured in this laboratory have specific binding sites with
much lower affinity for somatostatin (unpublished data) than
those described by Setyono-Han et al. (1987); such sites
would require higher concentrations of peptide to achieve an
effective degree of receptor occupancy. Secretion of SLI by
the cells and possible interactions of endogenous somatosta-
tin with high affinity receptors on the cells is currently being
investigated.
These differences in receptor affinity and dose response
may be due to differences in culture conditions. It has been
shown that the mitogenic response of MCF-7 cells to
oestrogen, for example, is determined by the species, type
and batch of serum used (Devleeschouwer et al., 1987). In
the investigations of Setyono-Han et al. (1987) the passaging
medium contained heat-inactivated serum and insulin while
the experimental medium contained heat- and charcoal-
treated serum. Scambia et al. (1988) used untreated serum
for passaging and charcoal-treated serum for growth experi-
ments. Results discussed here were obtained from cells
passaged and tested in untreated serum. The failure of
insulin to enhance the inhibitory effects of somatostatin and
Sandostatin in our experiments may also be due to differ-
ences in culture conditions.
Since SLI is rarely found in breast cancer specimens, its
synthesis by the three breast cancer cell lines is surprising.
This may be a result of long-term tissue culture or may
indicate neuroendocrine differentiation. No studies have
investigated the association of somatostatin receptor posi-
tivity with synthesis of SLI in breast cancer. The synthesis of
SLI by these cells may be clinically relevant since autocrine
saturation of high affinity receptors may make cells refrac-
tory to low concentrations of somatostatin. Results reported
here suggest that higher doses may be effective in these
circumstances.
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